$MAPP Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in MAP Pharmaceuticals, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in MAP Pharmaceuticals, Inc.. Get notifications about new insider transactions in MAP Pharmaceuticals, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 05 2013 | MAPP | MAP Pharmaceutical ... | MCPHERRON MATTHEW V | Director | Option Exercise | D | 11.69 | 10,000 | 116,900 | 0 | |
| Mar 05 2013 | MAPP | MAP Pharmaceutical ... | MCPHERRON MATTHEW V | Director | Option Exercise | D | 16.47 | 7,500 | 123,525 | 0 | |
| Mar 05 2013 | MAPP | MAP Pharmaceutical ... | MCPHERRON MATTHEW V | Director | Option Exercise | D | 14.77 | 7,500 | 110,775 | 0 | |
| Mar 05 2013 | MAPP | MAP Pharmaceutical ... | MCPHERRON MATTHEW V | Director | Option Exercise | D | 3.18 | 7,500 | 23,850 | 0 | |
| Mar 05 2013 | MAPP | MAP Pharmaceutical ... | MCPHERRON MATTHEW V | Director | Option Exercise | D | 12.19 | 7,500 | 91,425 | 0 | |
| Mar 05 2013 | MAPP | MAP Pharmaceutical ... | MCPHERRON MATTHEW V | Director | Sell | U | 25.00 | 2,999,526 | 74,988,150 | 0 | 3 M to 0 (-100.00 %) |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | CHAI CHRISTOPHER Y | SVP, Chief Financia ... | Option Exercise | D | 0.00 | 8,250 | 0 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | CHAI CHRISTOPHER Y | SVP, Chief Financia ... | Option Exercise | D | 0.00 | 4,500 | 0 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | CHAI CHRISTOPHER Y | SVP, Chief Financia ... | Option Exercise | D | 14.09 | 32,500 | 457,925 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | CHAI CHRISTOPHER Y | SVP, Chief Financia ... | Option Exercise | D | 16.15 | 27,500 | 444,125 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | CHAI CHRISTOPHER Y | SVP, Chief Financia ... | Option Exercise | D | 16.19 | 55,000 | 890,450 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | CHAI CHRISTOPHER Y | SVP, Chief Financia ... | Option Exercise | D | 10.37 | 75,000 | 777,750 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | CHAI CHRISTOPHER Y | SVP, Chief Financia ... | Option Exercise | D | 13.12 | 60,000 | 787,200 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | CHAI CHRISTOPHER Y | SVP, Chief Financia ... | Option Exercise | D | 6.39 | 47,296 | 302,221 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | CHAI CHRISTOPHER Y | SVP, Chief Financia ... | Option Exercise | D | 3.36 | 11,299 | 37,965 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | CHAI CHRISTOPHER Y | SVP, Chief Financia ... | Option Exercise | D | 0.74 | 23,122 | 17,110 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | CHAI CHRISTOPHER Y | SVP, Chief Financia ... | Sell | U | 25.00 | 14,220 | 355,500 | 0 | 14.2 K to 0 (-100.00 %) |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | KELLEY BERNARD J | Director | Option Exercise | D | 11.69 | 10,000 | 116,900 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | KELLEY BERNARD J | Director | Option Exercise | D | 16.47 | 7,500 | 123,525 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | KELLEY BERNARD J | Director | Option Exercise | D | 14.77 | 7,500 | 110,775 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | KELLEY BERNARD J | Director | Option Exercise | D | 3.18 | 7,500 | 23,850 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | KELLEY BERNARD J | Director | Option Exercise | D | 12.19 | 7,500 | 91,425 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | KELLEY BERNARD J | Director | Option Exercise | D | 6.39 | 16,949 | 108,304 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | NELSON TIMOTHY S | President and CEO | Option Exercise | D | 0.00 | 28,125 | 0 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | NELSON TIMOTHY S | President and CEO | Option Exercise | D | 14.09 | 112,500 | 1,585,125 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | NELSON TIMOTHY S | President and CEO | Option Exercise | D | 16.15 | 200,000 | 3,230,000 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | NELSON TIMOTHY S | President and CEO | Option Exercise | D | 16.19 | 100,000 | 1,619,000 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | NELSON TIMOTHY S | President and CEO | Option Exercise | D | 10.37 | 175,000 | 1,814,750 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | NELSON TIMOTHY S | President and CEO | Option Exercise | D | 13.12 | 160,000 | 2,099,200 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | NELSON TIMOTHY S | President and CEO | Option Exercise | D | 6.39 | 180,790 | 1,155,248 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | NELSON TIMOTHY S | President and CEO | Option Exercise | D | 3.36 | 121,468 | 408,132 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | NELSON TIMOTHY S | President and CEO | Option Exercise | D | 0.74 | 179,176 | 132,590 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | NELSON TIMOTHY S | President and CEO | Option Exercise | D | 0.64 | 71,509 | 45,766 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | NELSON TIMOTHY S | President and CEO | Option Exercise | D | 0.64 | 132,549 | 84,831 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | NELSON TIMOTHY S | President and CEO | Sell | U | 25.00 | 38,740 | 968,500 | 0 | 38.7 K to 0 (-100.00 %) |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | ARMER THOMAS A | Chief Scientific Of ... | Option Exercise | D | 0.00 | 8,250 | 0 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | ARMER THOMAS A | Chief Scientific Of ... | Option Exercise | D | 0.00 | 4,500 | 0 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | ARMER THOMAS A | Chief Scientific Of ... | Option Exercise | D | 14.09 | 32,500 | 457,925 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | ARMER THOMAS A | Chief Scientific Of ... | Option Exercise | D | 16.15 | 27,500 | 444,125 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | ARMER THOMAS A | Chief Scientific Of ... | Option Exercise | D | 16.19 | 50,000 | 809,500 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | ARMER THOMAS A | Chief Scientific Of ... | Option Exercise | D | 10.37 | 75,000 | 777,750 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | ARMER THOMAS A | Chief Scientific Of ... | Option Exercise | D | 13.12 | 50,000 | 656,000 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | ARMER THOMAS A | Chief Scientific Of ... | Option Exercise | D | 6.39 | 22,526 | 143,941 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | ARMER THOMAS A | Chief Scientific Of ... | Option Exercise | D | 3.36 | 40,847 | 137,246 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | ARMER THOMAS A | Chief Scientific Of ... | Sell | U | 25.00 | 222,676 | 5,566,900 | 0 | 222.7 K to 0 (-100.00 %) |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Friedman Charlene A | SVP, Gen Counsel & ... | Option Exercise | D | 0.00 | 8,250 | 0 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Friedman Charlene A | SVP, Gen Counsel & ... | Option Exercise | D | 0.00 | 4,500 | 0 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Friedman Charlene A | SVP, Gen Counsel & ... | Option Exercise | D | 14.09 | 32,500 | 457,925 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Friedman Charlene A | SVP, Gen Counsel & ... | Option Exercise | D | 16.15 | 27,500 | 444,125 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Friedman Charlene A | SVP, Gen Counsel & ... | Option Exercise | D | 16.19 | 55,000 | 890,450 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Friedman Charlene A | SVP, Gen Counsel & ... | Option Exercise | D | 10.37 | 50,805 | 526,848 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Friedman Charlene A | SVP, Gen Counsel & ... | Option Exercise | D | 13.12 | 30,000 | 393,600 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Friedman Charlene A | SVP, Gen Counsel & ... | Option Exercise | D | 12.37 | 74,744 | 924,583 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Friedman Charlene A | SVP, Gen Counsel & ... | Sell | U | 25.00 | 4,229 | 105,725 | 0 | 4.2 K to 0 (-100.00 %) |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | GIANAKAKOS ANASTASIOS | SVP, Chief Business ... | Option Exercise | D | 0.00 | 8,250 | 0 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | GIANAKAKOS ANASTASIOS | SVP, Chief Business ... | Option Exercise | D | 0.00 | 4,500 | 0 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | GIANAKAKOS ANASTASIOS | SVP, Chief Business ... | Option Exercise | D | 14.09 | 32,500 | 457,925 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | GIANAKAKOS ANASTASIOS | SVP, Chief Business ... | Option Exercise | D | 16.15 | 27,500 | 444,125 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | GIANAKAKOS ANASTASIOS | SVP, Chief Business ... | Option Exercise | D | 16.19 | 45,000 | 728,550 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | GIANAKAKOS ANASTASIOS | SVP, Chief Business ... | Option Exercise | D | 10.37 | 50,000 | 518,500 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | GIANAKAKOS ANASTASIOS | SVP, Chief Business ... | Option Exercise | D | 13.12 | 40,000 | 524,800 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | GIANAKAKOS ANASTASIOS | SVP, Chief Business ... | Sell | U | 25.00 | 18,438 | 460,950 | 0 | 18.4 K to 0 (-100.00 %) |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | KELLERMAN DONALD J | SVP,Clinical Dev & ... | Option Exercise | D | 0.00 | 8,250 | 0 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | KELLERMAN DONALD J | SVP,Clinical Dev & ... | Option Exercise | D | 0.00 | 4,500 | 0 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | KELLERMAN DONALD J | SVP,Clinical Dev & ... | Option Exercise | D | 14.09 | 32,500 | 457,925 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | KELLERMAN DONALD J | SVP,Clinical Dev & ... | Option Exercise | D | 16.15 | 27,500 | 444,125 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | KELLERMAN DONALD J | SVP,Clinical Dev & ... | Option Exercise | D | 16.19 | 55,000 | 890,450 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | KELLERMAN DONALD J | SVP,Clinical Dev & ... | Option Exercise | D | 10.37 | 29,500 | 305,915 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | KELLERMAN DONALD J | SVP,Clinical Dev & ... | Option Exercise | D | 9.20 | 61,450 | 565,340 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | KELLERMAN DONALD J | SVP,Clinical Dev & ... | Sell | U | 25.00 | 3,795 | 94,875 | 0 | 3.8 K to 0 (-100.00 %) |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 0.00 | 750 | 0 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 0.00 | 300 | 0 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 0.00 | 8,250 | 0 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 0.00 | 3,375 | 0 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 0.00 | 3,500 | 0 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 14.09 | 3,000 | 42,270 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 16.15 | 1,800 | 29,070 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 16.19 | 4,375 | 70,831 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 10.37 | 5,000 | 51,850 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 13.12 | 2,500 | 32,800 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 6.39 | 4,237 | 27,074 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 3.36 | 248 | 833 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 14.09 | 32,500 | 457,925 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 15.38 | 13,750 | 211,475 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 16.15 | 21,000 | 339,150 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 16.19 | 35,000 | 566,650 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 10.37 | 51,500 | 534,055 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 13.12 | 10,000 | 131,200 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 6.39 | 1,589 | 10,154 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | D | 3.36 | 1,648 | 5,537 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Sell | U | 25.00 | 12,951 | 323,775 | 0 | 13 K to 0 (-100.00 %) |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Wolff Henry Ward | Director | Option Exercise | D | 11.69 | 10,000 | 116,900 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Wolff Henry Ward | Director | Option Exercise | D | 16.47 | 7,500 | 123,525 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Wolff Henry Ward | Director | Option Exercise | D | 14.77 | 7,500 | 110,775 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Wolff Henry Ward | Director | Option Exercise | D | 3.18 | 7,500 | 23,850 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | Wolff Henry Ward | Director | Option Exercise | D | 12.74 | 30,000 | 382,200 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | WARD SCOTT R | Director | Option Exercise | D | 11.69 | 10,000 | 116,900 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | WARD SCOTT R | Director | Option Exercise | D | 16.47 | 7,500 | 123,525 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | WARD SCOTT R | Director | Option Exercise | D | 14.77 | 7,500 | 110,775 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | WARD SCOTT R | Director | Option Exercise | D | 3.18 | 7,500 | 23,850 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | WARD SCOTT R | Director | Option Exercise | D | 8.98 | 30,000 | 269,400 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | WARD SCOTT R | Director | Sell | U | 25.00 | 2,000 | 50,000 | 0 | 2 K to 0 (-100.00 %) |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | OSHEA WILLIAM J | Director | Option Exercise | D | 13.79 | 20,000 | 275,800 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | HENWOOD GERALDINE | Director | Option Exercise | D | 11.69 | 5,000 | 58,450 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | HENWOOD GERALDINE | Director | Option Exercise | D | 16.47 | 7,500 | 123,525 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | HENWOOD GERALDINE | Director | Option Exercise | D | 14.77 | 7,500 | 110,775 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | GIANAKAKOS ANASTASIOS | SVP, Chief Business ... | Option Exercise | M | 10.37 | 20,000 | 207,400 | 50,000 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | GIANAKAKOS ANASTASIOS | SVP, Chief Business ... | Sell | S | 25.00 | 20,000 | 500,000 | 18,438 | 38.4 K to 18.4 K (-52.03 %) |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | GIANAKAKOS ANASTASIOS | SVP, Chief Business ... | Buy | M | 10.37 | 20,000 | 207,400 | 38,438 | 18.4 K to 38.4 K (+108.47 %) |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | HENWOOD GERALDINE | Director | Option Exercise | M | 12.19 | 7,500 | 91,425 | 0 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | HENWOOD GERALDINE | Director | Option Exercise | M | 11.69 | 2,500 | 29,225 | 5,000 | |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | HENWOOD GERALDINE | Director | Sell | S | 25.00 | 10,000 | 250,000 | 0 | 10 K to 0 (-100.00 %) |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | HENWOOD GERALDINE | Director | Buy | M | 12.19 | 7,500 | 91,425 | 10,000 | 2.5 K to 10 K (+300.00 %) |
| Mar 04 2013 | MAPP | MAP Pharmaceutical ... | HENWOOD GERALDINE | Director | Buy | M | 11.69 | 2,500 | 29,225 | 2,500 | 0 to 2.5 K |
| Feb 04 2013 | MAPP | MAP Pharmaceutical ... | KELLERMAN DONALD J | SVP,Clinical Dev & ... | Sell | S | 24.73 | 1,429 | 35,339 | 3,479 | 4.9 K to 3.5 K (-29.12 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | M | 0.00 | 1,900 | 0 | 3,800 | |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Option Exercise | M | 0.00 | 3,000 | 0 | 9,000 | |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Sell | S | 24.75 | 764 | 18,909 | 12,294 | 13.1 K to 12.3 K (-5.85 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Buy | M | 0.00 | 1,900 | 0 | 13,058 | 11.2 K to 13.1 K (+17.03 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Payment of Exercise | F | 24.75 | 1,317 | 32,596 | 11,158 | 12.5 K to 11.2 K (-10.56 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | Borland Scott | SVP, Neurology Fran ... | Buy | M | 0.00 | 3,000 | 0 | 12,475 | 9.5 K to 12.5 K (+31.66 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | ARMER THOMAS A | Chief Scientific Of ... | Option Exercise | M | 0.00 | 2,250 | 0 | 4,500 | |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | ARMER THOMAS A | Chief Scientific Of ... | Option Exercise | M | 0.00 | 2,750 | 0 | 8,250 | |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | ARMER THOMAS A | Chief Scientific Of ... | Payment of Exercise | F | 24.75 | 846 | 20,939 | 132,282 | 133.1 K to 132.3 K (-0.64 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | ARMER THOMAS A | Chief Scientific Of ... | Buy | M | 0.00 | 2,250 | 0 | 133,128 | 130.9 K to 133.1 K (+1.72 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | ARMER THOMAS A | Chief Scientific Of ... | Payment of Exercise | F | 24.75 | 1,034 | 25,592 | 130,878 | 131.9 K to 130.9 K (-0.78 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | ARMER THOMAS A | Chief Scientific Of ... | Buy | M | 0.00 | 2,750 | 0 | 131,912 | 129.2 K to 131.9 K (+2.13 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | GIANAKAKOS ANASTASIOS | SVP, Chief Business ... | Option Exercise | M | 0.00 | 2,250 | 0 | 4,500 | |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | GIANAKAKOS ANASTASIOS | SVP, Chief Business ... | Option Exercise | M | 0.00 | 2,750 | 0 | 8,250 | |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | GIANAKAKOS ANASTASIOS | SVP, Chief Business ... | Payment of Exercise | F | 24.75 | 846 | 20,939 | 17,450 | 18.3 K to 17.5 K (-4.62 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | GIANAKAKOS ANASTASIOS | SVP, Chief Business ... | Buy | M | 0.00 | 2,250 | 0 | 18,296 | 16 K to 18.3 K (+14.02 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | GIANAKAKOS ANASTASIOS | SVP, Chief Business ... | Payment of Exercise | F | 24.75 | 1,034 | 25,592 | 16,046 | 17.1 K to 16 K (-6.05 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | GIANAKAKOS ANASTASIOS | SVP, Chief Business ... | Buy | M | 0.00 | 2,750 | 0 | 17,080 | 14.3 K to 17.1 K (+19.19 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | Friedman Charlene A | SVP, Gen Counsel & ... | Option Exercise | M | 0.00 | 2,250 | 0 | 4,500 | |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | Friedman Charlene A | SVP, Gen Counsel & ... | Option Exercise | M | 0.00 | 2,750 | 0 | 8,250 | |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | Friedman Charlene A | SVP, Gen Counsel & ... | Payment of Exercise | F | 24.75 | 871 | 21,557 | 4,229 | 5.1 K to 4.2 K (-17.08 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | Friedman Charlene A | SVP, Gen Counsel & ... | Buy | M | 0.00 | 2,250 | 0 | 5,100 | 2.9 K to 5.1 K (+78.95 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | Friedman Charlene A | SVP, Gen Counsel & ... | Payment of Exercise | F | 24.75 | 1,207 | 29,873 | 2,850 | 4.1 K to 2.9 K (-29.75 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | Friedman Charlene A | SVP, Gen Counsel & ... | Buy | M | 0.00 | 2,750 | 0 | 4,057 | 1.3 K to 4.1 K (+210.41 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | CHAI CHRISTOPHER Y | SVP, Chief Financia ... | Option Exercise | M | 0.00 | 2,250 | 0 | 4,500 | |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | CHAI CHRISTOPHER Y | SVP, Chief Financia ... | Option Exercise | M | 0.00 | 2,750 | 0 | 8,250 | |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | CHAI CHRISTOPHER Y | SVP, Chief Financia ... | Payment of Exercise | F | 24.75 | 873 | 21,607 | 13,899 | 14.8 K to 13.9 K (-5.91 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | CHAI CHRISTOPHER Y | SVP, Chief Financia ... | Buy | M | 0.00 | 2,250 | 0 | 14,772 | 12.5 K to 14.8 K (+17.97 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | CHAI CHRISTOPHER Y | SVP, Chief Financia ... | Payment of Exercise | F | 24.75 | 1,207 | 29,873 | 12,522 | 13.7 K to 12.5 K (-8.79 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | CHAI CHRISTOPHER Y | SVP, Chief Financia ... | Buy | M | 0.00 | 2,750 | 0 | 13,729 | 11 K to 13.7 K (+25.05 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | KELLERMAN DONALD J | SVP,Clinical Dev & ... | Option Exercise | M | 0.00 | 2,250 | 0 | 4,500 | |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | KELLERMAN DONALD J | SVP,Clinical Dev & ... | Option Exercise | M | 0.00 | 2,750 | 0 | 8,250 | |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | KELLERMAN DONALD J | SVP,Clinical Dev & ... | Payment of Exercise | F | 24.75 | 871 | 21,557 | 4,908 | 5.8 K to 4.9 K (-15.07 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | KELLERMAN DONALD J | SVP,Clinical Dev & ... | Buy | M | 0.00 | 2,250 | 0 | 5,779 | 3.5 K to 5.8 K (+63.76 %) |
| Jan 29 2013 | MAPP | MAP Pharmaceutical ... | KELLERMAN DONALD J | SVP,Clinical Dev & ... | Payment of Exercise | F | 24.75 | 1,207 | 29,873 | 3,529 | 4.7 K to 3.5 K (-25.49 %) |